This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Book4Time + Nonius Hospitality Technology, a collaboration that marks a significant advancement in creating a more integrated, seamless, and satisfying digital journey for guests worldwide. Nonius, a leader in guest technology solutions, offers a comprehensive suite for a contactless digital guest journey.
Cluff Named Chief Executive Officer and Patrick Johnson to Serve as Executive Chairman and Chief Innovation Officer of BioPhotas, Inc. Denise Ryan has been promoted to the position of Chief Clinical Affairs Officer. Wayne (Tony) May has been promoted to Chief Financial Officer and Treasurer. BioPhotas, Inc.,
Ligand Pharmaceuticals is launching Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and has appointed Scott Plesha as Chief Executive Officer to accelerate the commercialization of berdazimer topical gel, 10.3% (Zelsuvmi) for the treatment of molluscum contagiosum. Pelthos is a wholly owned subsidiary of Ligand.
Being located in residential areas or near office complexes ensures convenience for clients, who often seek beauty services during their free time or after work. Beauty businesses strategically position themselves in areas with a high concentration of residential complexes or office buildings.
Being located in residential areas or near office complexes ensures convenience for clients, who often seek beauty services during their free time or after work. Beauty businesses strategically position themselves in areas with a high concentration of residential complexes or office buildings.
Travelers don’t just want to choose their own adventure – they want to maximize every moment of their time away,” said Chris Nassetta, president and chief executive officer, Hilton. Motto by Hilton has equipped its rooms with top-notch mattresses, sound-absorbing surroundings and smart technology available through the Hilton Honors app.
Arash Khazei will step down as Chief Executive Officer, continuing in the near term as a strategic advisor to the company. ELEVAI Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology Elevai Labs, Inc. Meet miraDry’s New CEO Industry vet Rob Catlin is the new CEO at miraDry.
. “XEOMIN is the first and only FDA-approved neurotoxin for the simultaneous treatment of upper facial lines (forehead lines, frown lines and crow’s feet lines),” says Dr. Samantha Kerr, Chief Scientific Officer at Merz Aesthetics, in a news release.
Aescape is in many ways the culmination of my experiences over the years and the representation of my biggest passions in life, which are my own personal wellness and health journey and in bringing technology and data-backed solutions to the improvement of our wellbeing.” There’s never any guesswork.
and Europe will complement the recent launch of Nuceiva, our flagship neurotoxin, which has been met with very strong interest and growing demand from customers,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. “We We are extremely excited to expand our partnership with Evolus beyond the U.S.
and Europe will complement the recent launch of Nuceiva, our flagship neurotoxin, which has been met with very strong interest and growing demand from customers,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. “We We are extremely excited to expand our partnership with Evolus beyond the U.S.
Through our partnership with rePurpose Global, we fund the recovery and processing of twice as much plastic waste from nature as we use in our bottle. Using cutting-edge technology, we deliver premium, plant-based vitamins D3 and K2 in coconut oil to make Smarter Vitamin D3 fully bioavailable.
FULLY BIOAVAILABLE VEGETABLE SOFTGELS | Using cutting edge technology, Smarter Nutrition Vitamin D3 is encapsulated in clinically proven and patented vegetarian softgels, free from chemical coatings, fillers, and synthetic binders. New Chapter is also Zero Manufacturing Waste to Landfill certified.
It’s pure commonsense ,” Nathan Jones, chief executive officer of Xlear said in a statement. Glenmark Pharmaceuticals has signed a partnership with Canadian company SaNOtize Research & Development Corp., Since Nature published this finding in 1993, nanobody technology has made notable progress in its application.
If you’re as obsessed with high-performance, medical-grade formulations as we are, buckle up because this is a partnership thats about to shake up the skincare game. Every product is clean, non-toxic, and created to work harmoniously with in-office aesthetic treatments. Why Epicutis?
This expansion will provide CMed Aesthetics with office space, a dedicated manufacturing facility for skincare, and a separate facility for medical devices. Our adventure took off from the mid of 2018, when we found good partnerships in Poland, then Ukraine, UK and Russia at the end of the year.
Dr Nermeen Varawalla, Chief Medical Officer of Scancell, says: Cancer vaccines have the potential to transform immunotherapy, redefine treatment options and ultimately save lives. Research into targeted cancer treatments is vital.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content